Isotretinoin
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
- Isotretinoin
- Isotretinoin: From Dermatological Use (Original Indication Not Recorded) to Malignant Renovascular Hypertension
Isotretinoin: From Dermatological Use (Original Indication Not Recorded) to Malignant Renovascular Hypertension
One-Sentence Summary
Isotretinoin is a retinoid registered in South Africa as an oral capsule (Oratane 5Mg) and a topical gel (Isotrex), but the registration data do not state its approved indication. The TxGNN model predicts it may be effective for malignant renovascular hypertension and malignant hypertensive renal disease. There are currently 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the SAHPRA licence data provided |
| Predicted New Indication | Malignant renovascular hypertension (a second prediction, malignant hypertensive renal disease, has the same score) |
| TxGNN Prediction Score | 99.01% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available, and the original indication is not recorded in the data provided. Isotretinoin is a retinoid, and this is the only mechanistic starting point available.
A speculative link exists through retinoid signalling. Preclinical work has reported that retinoic acid can modulate renin expression and renal inflammation or fibrosis. That could in theory touch the renin-angiotensin system, which is central to renovascular hypertension. This link was not verified against the provided data. It does not show that isotretinoin lowers blood pressure or protects the kidney.
The two predicted diseases have identical scores (99.01%, ranks 4772 and 4773). They probably come from the same overlapping disease neighbourhood in the knowledge graph, so they should be read as one weak signal, not two independent ones.
Clinical Trial Evidence
Currently no related clinical trials registered. No ClinicalTrials.gov, ICTRP, SANCTR or PACTR entries were found for either predicted indication.
Literature Evidence
Currently no related literature available.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 43/13.4.2/0746 | Oratane 5Mg | Capsule (oral) | Not stated in the data provided |
| Reg. No. 29/13.12/0027 | Isotrex | Gel (topical) | Not stated in the data provided |
Essential Medicines List (EML) status was not included in the data provided.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Isotretinoin is known to be teratogenic and can cause dyslipidaemia, so hepatic and lipid monitoring would be a concern. No data were provided on its use in renovascular disease or severe renal impairment.
Conclusion and Next Steps
Decision: Hold
Rationale: The only support is a model score. There are no trials or publications, and the mechanism and original indication are not documented. The known safety profile (teratogenicity, lipid effects) is a further reason for caution in a severely ill hypertensive population.
To proceed, the following is needed:
- The SAHPRA Professional Information (indications, warnings, contraindications), which currently blocks safety screening
- Mechanism of action data, for example from DrugBank
- A systematic literature search on retinoids and renin, renal fibrosis or hypertension, followed by preclinical validation
- A safety assessment for patients with severe hypertension and renal impairment
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.